Biologics Contract Development Market Report 2025

The biologics contract development market size has grown rapidly in recent years. It will grow from $7.75 billion in 2024 to $8.58 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to biologics market growth, rise in biopharmaceuticals, complexity of biologics, patent expirations, cost efficiency.

The biologics contract development market size is expected to see rapid growth in the next few years. It will grow to $13.19 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to digitalization and data analytics, risk management, flexibility and scalability, burgeoning investment in r&d, precision medicine and personalized therapies. Major trends in the forecast period include regenerative medicine, risk mitigation strategies, global collaborations, advanced technologies, technological integration.

The increasing prevalence of chronic diseases is projected to drive the growth of the biologics contract development market in the coming years. Chronic diseases are defined as illnesses lasting a year or longer that require ongoing medical attention. The rise in chronic disease cases is leading to a higher demand for the development of novel drugs, including biologics, thereby promoting the biologics contract development market. For instance, reports from the Office for Health Improvement & Disparities, a UK government body, indicated that in the first half of 2023, there were 3,940 excess deaths due to chronic lower respiratory diseases, representing a 30% increase compared to expected rates. By the end of the year, this figure rose to 5,363, reflecting an overall increase of 22%. Consequently, the growing prevalence of chronic diseases is set to drive the expansion of the biologics contract development market.

The rising investment in biopharmaceuticals is significantly fueling the growth of the biologics contract development market in the future. The increasing demand for biopharmaceuticals, such as monoclonal antibodies, recombinant proteins, and gene therapies, is prompting companies to outsource development activities to meet market needs. For example, a report published in April 2024 by Deloitte Touche Tohmatsu Limited (DTTL), a UK-based pharmaceutical company, indicated that total reported R&D spending in the biopharmaceutical sector rose from $139.2 billion in 2022 to $145.5 billion in 2023, representing a 4.5% increase. Therefore, the growing investment in biopharmaceuticals is expected to drive the biologics contract development market.

Technological advancements are reshaping the biologics contract development market, with major players incorporating advanced technologies to maintain their market standing. In January 2022, Lonza introduced the bYlok technology platform, designed to facilitate the design and manufacture of bispecific antibodies. This platform addresses challenges related to light-heavy chain mispairing, ensuring high yields, accuracy exceeding 95%, and compatibility with a monoclonal antibody (mAb)-like format. Technological innovation remains a focal point in sustaining competitiveness within the biologics contract development sector.

Major companies operating in the biologics contract development arena are integrating data analytics into their processes, fostering improved monitoring, analysis, and decision-making. This integration of digital technologies enhances efficiency and productivity in biologics development. In October 2022, Evotec SE launched PanHunter, part of the PanOmics data access and analytics technology, which enables advanced patient population stratification and prediction of efficacy and toxicity profiles. This incorporation of data analytics signifies a strategic move towards leveraging digital tools for enhanced insights in the biologics contract development market.

Strategic acquisitions play a pivotal role in reinforcing companies' positions in the biologics contract development market. In February 2022, Recipharm acquired Vibalogics and Arranta Bio, strengthening its presence in advanced therapy medicinal products and expanding virotherapy manufacturing capabilities in the US. Vibalogics and Arranta Bio, both contract development and manufacturing organizations, were pivotal acquisitions contributing to Recipharm's strategic growth in the biologics contract development sector.

Major companies operating in the biologics contract development market are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., AbbVie Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Meridian Life Science Inc., Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Sartorius AG, Syngene International Limited, Vibalogics GmbH, Yposkesi.

North America was the largest region in the biologics contract development market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics contract development market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biologics contract development market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Biologics contract development involves companies that offer development and manufacturing services for biologics on a contractual basis to pharmaceutical firms. This outsourcing approach allows pharmaceutical companies to concentrate on marketing, research and development (R&D), and brand-building activities while entrusting the manufacturing of biologics to external service providers.

The primary sources for biologics contract development include microbial, mammalian, and other sources. Microbial sources are utilized in the production of various biologics. Biologics contract development caters to various indications, including oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others. The product services offered in biologics contract development encompass cell line development, process development, and other related services.

The biologics contract development market research report is one of a series of new reports that provides biologics contract development market statistics, including biologics contract development industry global market size, regional shares, competitors with a biologics contract development market share, detailed biologics contract development market segments, market trends and opportunities, and any further data you may need to thrive in the biologics contract development industry. This biologics contract development market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The biologics contract development market includes revenues earned by entities by sourcing, solid and specialized formulation development, and process analytics development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.